Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients
with (quasi) identical, stereotyped B-cell receptor (BcR) immunoglobulins. Patients in certain …

Chronic lymphocytic leukemia is a complex and heterogeneous hematological malignancy.
The advance of high-throughput multi-omics technologies has significantly influenced …

The p53 family member p63 exists as two major protein variants (TAp63 and ΔNp63) with
distinct expression patterns and functional properties. Whilst downstream target genes of …

The clonotypic B cell receptor immunoglobulin (BcR IG) plays a seminal role in B cell
lymphoma development and evolution. From a clinical perspective, this view is supported by …

Sequence convergence, otherwise stereotypy, of B-cell receptor immunoglobulin (BcR IG)
from unrelated patients is a distinctive feature of the IG gene repertoire in chronic …

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with alterations in genetic
expression and epigenetic modifications. In recent years, the new insight into epigenetics in …

The ontogeny and evolution of chronic lymphocytic leukemia (CLL) are critically dependent
on interactions between leukemic cells and their microenvironment, including antigens, the …

The chromatin activation landscape of chronic lymphocytic leukemia (CLL) with stereotyped
B-cell receptor immunoglobulin is currently unknown. In this study, we report the results of a …

The p63 protein is a master regulatory transcription factor that plays crucial roles in cell
differentiation, adult tissue homeostasis, and chromatin remodeling, and its dysregulation is …

Subset# 201 is a clinically indolent subgroup of patients with chronic lymphocytic leukemia
defined by the expression of stereotyped, mutated IGHV4-34/IGLV1-44 BCR Ig. Subset# 201 …